Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA

KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This multicenter, single-arm, open-label, early exploratory clinical study is designed to evaluate the preliminary safety and efficacy of KSVCBD injection in patients with relapsed or refractory (r/r) multiple myeloma(MM) expressing CD19 and/or BCMA.

Trial Details

NCT ID
NCT07620275
Phase
PHASE1
Sponsor
Chinese PLA General Hospital
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • KSVCBD injection
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Age 18-75 years (inclusive), any gender.
  • Subjects must meet the following diagnostic and treatment criteria:
  • 1 According to the IMWG 2014 diagnostic criteria, subjects must have a confirmed diagnosis of multiple myeloma and be in a relapsed or refractory s…
  • Must have received at least 3 prior lines of MM therapy (including a proteasome inhibitor and an immunomodulatory agent). consecutive cycles of ind…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →